US Patent

US9737469 — Methods for treating hair loss disorders

Method of Use · Assigned to Columbia University in the City of New York · Expires 2031-11-02 · 5y remaining

Vulnerability score 76/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating hair loss disorders by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.

USPTO Abstract

The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.

Drugs covered by this patent

Olumiant (baricitinib) · Eli Lilly

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3500`	—	Olumiant
`U-3500`	—	Olumiant
`U-3500`	—	Olumiant

Patent Metadata

Patent number: US9737469
Jurisdiction: US
Classification: Method of Use
Expires: 2031-11-02
Drug substance claim: No
Drug product claim: No
Assignee: Columbia University in the City of New York
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.